SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
Level 5, 126 Philip Street Sydney NSW 2000 GPO Box 5193 Sydney NSW 2001
Tel : 1300 288 664 or +61 2 9698 5414The suspension of trading in the options of Paradigm Biopharmaceuticals Limited will be lifted immediately. | 28/11/2023 |
The options of Paradigm Biopharmaceuticals Limited will be suspended immediately in accordance with Listing Rule 17.3, as there will be no deferred settlement trading. The options are expected to be quoted on a normal settlement basis on Tuesday, 28 November 2023. The suspension only applies to PAR's options and does not apply to any other quoted securities of PAR. | 21/11/2023 |
The suspension of trading in the securities of Paradigm Biopharmaceutics Limited will be lifted immediately, following the release by PAR of an announcement regarding the completion of a capital raising. | 08/04/2020 |
Bids received significantly exceeded the size of the placement. PAR fully funded to Phase 3 OA trial completion and readout. Support from large Australian and International institutional investors. Significant endorsement of PAR and its treatment of OA. Capital raising enables PAR to be focused on the clear path to regulatory approval and commercialisation. | 08/04/2020 |
The company releases a notice of Proposed issue of Securities - PAR. | 08/04/2020 |
The company will host a conference call at 8:30am (AEST) Wednesday 8th April to discuss the recent minutes provided by the US FDA and guidance over the requirements for the Phase 3 clinical trial design and NDA submission. The company will also discuss the recent SAS data on 34 patients who have been treated using the Phase 3 material and measured with the same endpoints that will be used in the Phase 3 clinical trials. Investors are encouraged to send through questions by 8:00pm (AEST) Tuesday 7th April, with the company collating questions sent and will endeavour to answer the most frequently asked. Questions are to be submitted to investorrelations@paradigmbiopharma.com. | 07/04/2020 |
Paradigm reports very encouraging real-world data ahead of its phase 3 OA clinical trial using the Phase 3 product and two Phase 3 endpoints. | 06/04/2020 |
The company receives clarity on US regulatory pathway. The pre-IND meeting was both positive and informative for Paradigm. The positive outcomes from the meeting were clear guidance around the primary and secondary endpoints for the Phase 3 clinical trial, the number of Phase 3 studies required for registration and overall clarity and guidance over the requirements for the Phase 3 clinical trial design and NDA submission. | 06/04/2020 |
The company releases its latest Corporate Presentation. | 06/04/2020 |
The securities of Paradigm Biopharmaceuticals Limited will be suspended from quotation immediately under Listing Rules 17.2, at the request of PAR, pending the release of an announcement regarding the proposed capital raising. | 06/04/2020 |
listed entity carried for record purposes only | 19/08/2015 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 15/10/2024 | Paul Rennie | 245,300 | $0.207 | $50,835.00 |
| 14/10/2024 | Matthew Fry | 350,000 | $0.209 | $73,250.00 |
| 18/05/2023 | Helen Fisher | 10,204 | $0.982 | $10,020.00 |
| 12/05/2023 | Paul Rennie | 73,851 | $1.029 | $76,001.00 |
| 19/12/2022 | Paul Rennie | 47,720 | $1.289 | $61,521.00 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Paul Rennie | Non Exec Chairman, Managing Director | 19/08/2015 |
| Donna Skerrett | Interim CEO | 03/07/2020 |
| Jeannie Joughin | COO | 03/06/2020 |
| Abby Niven | CFO | 03/03/2023 |
| Amos Meltzer | Independent Director | 08/12/2020 |
| Matthew Fry | Non Exec Director | 04/03/2024 |
| Abby Macnish | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
